<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858715</url>
  </required_header>
  <id_info>
    <org_study_id>Vienna REACT</org_study_id>
    <nct_id>NCT00858715</nct_id>
  </id_info>
  <brief_title>Resistance to Antithrombotic Therapy</brief_title>
  <acronym>Vienna REACT</acronym>
  <official_title>Resistance to Antithrombotic Therapy in Patients Undergoing Angioplasty and Stenting for Cardiovascular Disease - Vienna REACT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel plays a pivotal role in the antithrombotic regimen after percutaneous
      intervention with stent implantation. However, response to clopidogrel shows a wide
      interindividual variability and a high on-treatment residual ADP-inducible platelet
      reactivity has already been associated with an increased risk for adverse events after
      coronary stenting. In the present study, platelet reactivity will be determined by 6
      different platelet function tests in patients on dual antiplatelet therapy after angioplasty
      and stenting for peripheral, coronary and carotid artery disease. One hundred patients
      showing high on-treatment residual ADP-inducible platelet reactivity in 2 or more tests will
      be randomized to receive either 75mg or 150mg of daily clopidogrel in addition to aspirin for
      3 months. The aim of the present study is to investigate the effects of intensified
      antithrombotic therapy (150mg clopidogrel + 100mg aspirin daily) versus standard
      antithrombotic therapy (75mg clopidogrel + 100mg aspirin daily) in patients with decreased
      clopidogrel-mediated platelet inhibition after percutaneous intervention with stent
      implantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of major adverse cardiovascular events (MACE)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurence of major adverse cardiovascular events (MACE)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Angioplasty</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg clopidogrel + 100 mg aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg clopidogrel + 100 mg aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>100 mg aspirin</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>75 mg (Arm 1) and 150 mg (Arm 2)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  angioplasty and stenting for peripheral, coronary or carotid artery disease

        Exclusion Criteria:

          -  known aspirin or clopidogrel intolerance

          -  therapy with vitamin K antagonists (warfarin, phenprocoumon, acenocoumarol)

          -  treatment with ticlopidine, dipyridamol or nonsteroidal antiinflammatory drugs

          -  family or personal history of bleeding disorders

          -  malignant paraproteinemias

          -  myeloproliferative disorders

          -  heparin-induced thrombocytopenia

          -  severe hepatic failure

          -  known qualitative defects in thrombocyte function

          -  major surgical procedure within one week before enrollment

          -  platelet count &lt; 100.000 or &gt; 450.000/Âµl

          -  hemoglobin &lt; 8 g/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph W. Kopp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Angiology/ Department of Internal Medicine II/ Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Angiology, Department of Internal Medicine II, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Christoph W. Kopp</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Antithrombotic therapy</keyword>
  <keyword>Platelet function testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

